Advertisement

Topics

Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris

01:30 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Meeting to highlight Company’s strategy to demonstrate the power of its immunotherapies in combination with immune checkpoint inhibitors (ICIs), the new standard of care in oncology Scientific prese...

Other Sources for this Article

Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
investorrelations@transgene.fr
or
Media contacts:
Citigate Dewe Rogerson
David Dible / Marine Perrier, + 44 (0)20 7638 9571
transgene@citigatedr.co.uk

NEXT ARTICLE

More From BioPortfolio on "Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...